日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

NRX-0492 degrades wild-type and C481 mutant BTK and demonstrates in vivo activity in CLL patient-derived xenografts

NRX-0492 可降解野生型和 C481 突变型 BTK,并在 CLL 患者来源的异种移植模型中显示出体内活性。

Deyi Zhang ,Hailey M Harris ,Jonathan Chen ,Jen Judy ,Gabriella James ,Aileen Kelly ,Joel McIntosh ,Austin Tenn-McClellan ,Eileen Ambing ,Ying Siow Tan ,Hao Lu ,Stefan Gajewski ,Matthew C Clifton ,Stephanie Yung ,Daniel W Robbins ,Mehdi Pirooznia ,Sigrid S Skånland ,Erika Gaglione ,Maissa Mhibik ,Chingiz Underbayev ,Inhye E Ahn ,Clare Sun ,Sarah E M Herman ,Mark Noviski ,Adrian Wiestner

Clinical and biological implications of target occupancy in CLL treated with the BTK inhibitor acalabrutinib

BTK 抑制剂阿卡替尼治疗慢性淋巴细胞白血病 (CLL) 的靶标占据率的临床和生物学意义

Clare Sun, Pia Nierman, Ellen K Kendall, Jean Cheung, Michael Gulrajani, Sarah E M Herman, Christopher Pleyer, Inhye E Ahn, Maryalice Stetler-Stevenson, Constance M Yuan, Irina Maric, Erika M Gaglione, Hailey M Harris, Stefania Pittaluga, Min Hui Wang, Priti Patel, Mohammed Z H Farooqui, Raquel Izum